Detalhes bibliográficos
| Ano de defesa: |
2023 |
| Autor(a) principal: |
SOUZA, Dayse Azevedo Coelho de
 |
| Orientador(a): |
AZEVEDO, Conceição de Maria Pedrozo e Silva de
|
| Banca de defesa: |
AZEVEDO, Conceição de Maria Pedrozo e Silva de
,
PESSOA, Debora Luana Ribeiro
,
SIMÕES, Vanda Maria Ferreira
,
SANTOS, Daniel Wagner de Castro Lima
|
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Federal do Maranhão
|
| Programa de Pós-Graduação: |
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE/CCBS
|
| Departamento: |
DEPARTAMENTO DE MEDICINA I/CCBS
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
https://tedebc.ufma.br/jspui/handle/tede/5112
|
Resumo: |
The virus that causes hepatitis B (HBV) is a DNA virus belonging to the Hepadnaviridae family, genus Orthohepadnavirus. It can be transmitted sexually, vertically and parenterally. Co-infection caused by the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV) occurs in considerable numbers and is related to the common transmission route of these viruses. The objective of this work is to characterize co- infection with the hepatitis B virus among people living with HIV (PLHIV) in a reference service. It was carried out from January 2022 to July 2023 in a reference hospital in the state of Maranhão for infectious-parasitic diseases and its population was PLHIV, with a clinical and serological diagnosis recorded in the medical record, aged 18 years or over, who were undergoing regular outpatient follow-up at the unit and presented results of serological markers for Hepatitis B in their medical records. Data were collected from 500 medical records based on the analysis of consultation records, carried out by the service's multidisciplinary team and compiled into an investigative form. A total of 301 records were included. 263 (87.37%) corresponded to PLHIV and 38 (12.62%) to co- infected patients (HIV and HBV). Among the co-infected patients, 21(55.26%) were between 41 and 60 years old, 35(92.11%) were male, 22(57.89%) were mixed race, 17(44.74%) were single, 11 (28.95%) had completed primary education and 38 (100%) were using antiretroviral therapy with tenofovir. Of the PLHIV, 96 individuals (36.50%) were vaccinated for hepatitis B. Of these, 37 (38.54%) received the four recommended doses of the vaccine, 82 (85.42%) had reactive Anti-HBs marker titers and 3(3 .13%) of these patients presented reactive Anti-HBs due to contact with HBV. In relation to laboratory tests, it can be seen that in the overall sample the TCD4+ cell count was less than 350mm3, with 114 (43.35%) in the PLHIV group and 19 (50%) in the group co- infected with Hepatitis B, while the HIV viral load was above 40 copies/mL, with 211 in the PLHIV group (80.23%) and 28 in the co-infected group (73.68%). Furthermore, it was identified that 38 (12.6%) people tested positive for HBsAg, 102 (38.78%) had non- reactive anti-Hbc, while 143 (54.37%) had reactive results for Anti-Hbc. HBs. As for HBeAg, 9 (23.68%) of patients co-infected with HIV and HBV had reactive results, while 21 (55.26%) had reactive results for Anti-HBe. Data regarding hepatitis B viral load indicated that the viral load was less than 2000 IU/ml in 10 (26.32%) of the patients, out of a total of 17 patients who underwent the test. Investigating the presence of the hepatitis B virus, by carrying out specific tests, and evaluating the vaccination status for HBV in PLHIV can play a crucial role in improving the prognosis in this population. |
